Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Haematology & Bone Marrow Transplant
Peripheral blood stem cell (pbsc) transplant
A peripheral blood stem cell (PBSC) transplant replaces damaged or diseased bone marrow with healthy blood-forming stem cells collected from circulating blood via apheresis. Used to treat haematological conditions such as leukaemia, lymphoma, and multiple myeloma, the procedure involves stem cell mobilisation, high-dose conditioning therapy, infusion, and careful haematological recovery monitoring under specialised inpatient isolation.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Haematology & Bone Marrow Transplant
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Peripheral Blood Stem Cell (PBSC) Transplant
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is a peripheral blood stem cell (pbsc) transplant and how does it work?
A peripheral blood stem cell (pbsc) transplant is a specialised haematological procedure that replaces diseased or damaged bone marrow with healthy blood-forming stem cells collected from circulating blood. Under normal conditions, haematopoietic stem cells reside primarily within bone marrow cavities. To collect these cells from the peripheral bloodstream, patients or donors receive growth factor injections that stimulate the marrow, causing progenitor cells to release into the vascular circulation.
Once mobilised, these cells are collected using an apheresis machine that separates the stem cells and returns the remaining blood. Following high-dose conditioning chemotherapy or radiotherapy to eradicate malignant cells, the harvested stem cells are infused intravenously to re-establish healthy blood production. Patients exploring comprehensive systemic treatment often review advanced oncology treatments in Turkey (hub) to coordinate their haematology care.
Does peripheral blood stem cell transplant work: clinical evidence and haematological outcomes
Decades of clinical research validated by the European Society for Blood and Marrow Transplantation (EBMT) and the American Society of Hematology confirm that peripheral blood stem cell transplantation is an effective, standard-of-care intervention for specific haematological malignancies. Its therapeutic success depends on whether the procedure is autologous (using the patient's own cells) or allogeneic (using cells from a matched donor).
In autologous transplantation, high-dose conditioning chemotherapy followed by stem cell rescue achieves prolonged progression-free survival in chemosensitive relapsed lymphoma and multiple myeloma. The infused cells rescue the bone marrow from lethal chemotherapy toxicity. In allogeneic transplantation for acute leukaemia and myelodysplasia, donor immune cells also provide a vital graft-versus-leukaemia effect, hunting residual cancer cells. However, clinical registries demonstrate that while curative potential is substantial, long-term outcomes depend on cytogenetic risk, disease stage at transplant, and complications such as graft-versus-host disease.
Autologous versus allogeneic PBSC transplantation: candidate eligibility and clinical indications
Candidate eligibility is determined using standardized physiological criteria such as the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI), assessing performance status and organ function rather than chronological age alone.
Autologous PBSC transplantation suits patients with:
- Multiple myeloma or relapsed Hodgkin and non-Hodgkin lymphoma responding to initial salvage chemotherapy.
- Preserved cardiac ejection fraction, adequate pulmonary diffusing capacity, and normal renal and liver function.
- Good performance status (ECOG score 0 to 1) capable of enduring intense, temporary marrow suppression.
Allogeneic transplantation suits high-risk acute myeloid leukaemia, acute lymphoblastic leukaemia, and severe aplastic anaemia where healthy donor stem cells are required. Candidates need an HLA-matched sibling, a matched unrelated donor, or an acceptable haploidentical family donor. Poor candidates include patients with uncontrolled systemic infections, severe end-stage organ disease, or active chemo-refractory leukaemia where transplant-related risks outweigh clinical benefits.
Step-by-step: from stem cell mobilisation and apheresis to infusion
The clinical process follows four sequential phases:
1. Mobilisation
Donors or autologous patients receive daily injections of granulocyte colony-stimulating factor (G-CSF, such as filgrastim) for four to five days. In difficult-to-mobilise patients, plerixafor is added to stimulate stem cell release from the marrow into circulating blood.
2. Apheresis Collection
The individual is connected to a continuous-flow apheresis device via a central venous catheter or peripheral veins. Blood is centrifuged to separate the mononuclear layer containing CD34+ stem cells, while red cells and plasma are returned. The target yield is at least 2.0 to 5.0 million CD34+ cells per kilogram. Autologous grafts are cryopreserved with DMSO in liquid nitrogen, while allogeneic cells are typically infused fresh.
3. Conditioning
Patients enter a protective HEPA-filtered isolation room to undergo conditioning chemotherapy—such as melphalan for myeloma, BEAM for lymphoma, or busulfan-cyclophosphamide for allogeneic recipients—lasting three to six days to eradicate malignant cells and suppress host immunity.
4. Infusion (Day Zero)
The stem cells are infused intravenously through a central line over 30 to 120 minutes. Pre-medications prevent reactions to cryoprotectants. The infused cells naturally migrate to the bone marrow stroma to commence engraftment.
Peripheral blood stem cell (pbsc) transplant cost and package inclusions
The total peripheral blood stem cell (pbsc) transplant cost reflects the clinical complexity of cellular therapy. Autologous procedures involve mobilisation, collection, cryopreservation, conditioning, and three weeks of isolation. Allogeneic transplants cost significantly more due to high-resolution HLA typing, donor search logistics, extended hospitalisation, and intensive immunosuppressive management.
When comparing peripheral blood stem cell (pbsc) transplant price quotes, patients should ensure packages include pre-transplant cardiac and pulmonary workups, mobilising agents, apheresis cycles, cell storage, conditioning drugs, 21 to 30 days in a HEPA-filtered isolation room, irradiated blood products, and prophylactic antimicrobials.
| Country | Autologous PBSC Transplant (Approximate) | Allogeneic PBSC Transplant (Approximate) | Key Package Elements |
|---|---|---|---|
| Turkey | €25,000 – €45,000 | €55,000 – €95,000 | Comprehensive workup, apheresis, conditioning, isolation room stay, initial supportive medicines |
| United Kingdom | €40,000 – €75,000 | €110,000 – €220,000 | Private inpatient admission, stem cell processing, intensive care contingency, supportive blood products |
| Germany | €50,000 – €90,000 | €130,000 – €260,000 | Pre-transplant workup, apheresis, HEPA-filtered isolation, standard post-engraftment outpatient care |
| United States | €120,000 – €250,000 | €300,000 – €750,000 | Inpatient room fees, conditioning chemotherapy, cellular laboratory processing, outpatient monitoring |
Unplanned expenses can arise if patients require secondary mobilisation cycles with plerixafor or extended intensive care for severe infection. Before travelling, individuals can request a personalised free quote to evaluate itemised logistical and clinical expenses.
Comparing stem cell sources: peripheral blood versus bone marrow and umbilical cord blood
Haematologists choose graft sources based on disease urgency, recipient age, and donor match availability. Peripheral blood stem cells account for over 75% of allogeneic and almost all autologous transplants due to practical collection and rapid haematological recovery.
| Stem Cell Modality | Collection Method | Engraftment Speed | Best Suited To | Typical Limitations |
|---|---|---|---|---|
| Peripheral Blood Stem Cells (PBSC) | Outpatient apheresis following G-CSF mobilisation | Rapid (neutrophils ~10–14 days, platelets ~12–16 days) | Adult haematological malignancies (multiple myeloma, lymphoma, leukaemia) | Higher incidence of chronic GvHD in allogeneic settings compared to marrow |
| Bone Marrow Harvest | Surgical aspiration from pelvic bones under general anaesthesia | Moderate (neutrophils ~16–22 days, platelets ~20–30 days) | Aplastic anaemia, paediatric leukaemia, situations where chronic GvHD risk must be minimised | Requires operating theatre, donor discomfort, slower immune reconstitution |
| Umbilical Cord Blood | Cryopreserved cord blood units retrieved from international banks | Slower (neutrophils ~20–30 days, platelets ~35–50 days) | Patients lacking a matched sibling or unrelated adult donor | Fixed cell dose limits use in large adults, delayed immune recovery, high infection vulnerability |
Peripheral blood yields faster neutrophil and platelet recovery than bone marrow, shortening the vulnerable aplastic phase. However, because PBSC grafts contain higher quantities of donor T-lymphocytes, they carry a slightly increased risk of chronic graft-versus-host disease in allogeneic settings, which requires careful immunosuppressive balance.
Hospitalisation timeline, engraftment milestones, and recovery
Understanding peripheral blood stem cell (pbsc) transplant recovery helps patients prepare for prolonged physical rehabilitation across defined milestones:
Days +1 to +10: Aplasia Phase
White blood cells and platelets drop to nadir levels following conditioning. Patients stay in positive-pressure HEPA-filtered isolation rooms, receiving transfusions, antiemetics, and prophylactic antimicrobials to manage fatigue, nausea, and oral mucositis.
Days +10 to +20: Engraftment
Engraftment occurs when absolute neutrophil counts exceed 0.5 x 10^9/L for three consecutive days and platelets rise above 20 x 10^9/L without transfusions. Mucositis subsides and fevers resolve as newly generated immune cells enter circulation.
Days +21 to +100: Early Outpatient Recovery
Following discharge, patients attend outpatient clinics several times weekly for blood monitoring and electrolyte support. Patients undertaking a peripheral blood stem cell (pbsc) transplant in Turkey generally remain nearby for 60 to 90 days post-infusion before returning home safely.
Months 3 to 12: Long-Term Reconstitution
Full immune recovery requires 6 to 12 months. Patients follow dietary restrictions, avoid public crowds, take prophylactic antibiotics, and complete revaccinations. Understanding how it works helps international patients navigate hospital admission schedules, visa arrangements, and inpatient logistics.
Treatment outcomes and realistic remission expectations
Success in stem cell transplantation is evaluated through objective cellular and molecular benchmarks rather than immediate physical changes. Before transplant, marrow biopsies and PET-CT scans establish baseline disease volume.
Post-transplant response is verified through complete haematological remission and chimerism testing. In allogeneic procedures, 100% donor chimerism confirms donor cells have fully repopulated the bone marrow. Sensitive minimal residual disease (MRD) assays via flow cytometry or PCR detect residual malignant cells down to one in a million normal cells.
Achieving MRD negativity significantly correlates with long-term progression-free survival. However, transplantation cannot guarantee permanent cure. Relapse remains a recognized risk depending on tumour genetics and may necessitate maintenance therapies or donor lymphocyte infusions.
Potential risks, graft-versus-host disease, and safety considerations
PBSC transplantation involves significant toxicities that require management by experienced transplant haematologists, adhering to safety protocols from the NHS and EBMT:
- Neutropenic Infection: Severe vulnerability to bacterial, viral (CMV, EBV), and fungal pathogens during aplasia requires immediate empiric intravenous antimicrobials.
- Graft-Versus-Host Disease (GvHD): In allogeneic transplants, donor T-cells may attack recipient tissues. Acute GvHD affects the skin, liver, and gut within 100 days; chronic GvHD can cause prolonged autoimmune-like symptoms affecting eyes, mouth, joints, and skin.
- Oral Mucositis: High-dose conditioning damages the gastrointestinal lining, causing painful oral ulcers requiring analgesia and intravenous nutrition.
- Sinusoidal Obstruction Syndrome: Chemo-induced liver endothelial injury causes painful hepatomegaly, fluid retention, and jaundice.
- Graft Failure: A rare failure of stem cells to engraft or secondary rejection, requiring emergency rescue therapy.
Comprehensive cellular therapies are integrated within accredited centres offering modern oncology treatments in Turkey (hub).
Selecting a specialised transplant centre, JACIE accreditation, and red flags
Selecting an international transplant centre demands thorough scrutiny of microbiological safety, clinical credentials, and emergency readiness. The benchmark of quality for cellular therapy is JACIE (Joint Accreditation Committee ISCT & EBMT) or FACT accreditation, verifying strict standards in stem cell harvesting, laboratory processing, and clinical care.
A qualified transplant hospital must feature positive-pressure HEPA-filtered rooms, on-site irradiated blood banking, and 24/7 dedicated haematology care.
Red flags when evaluating clinics include:
- Unregulated clinics advertising unproven stem cell injections for neurological or cosmetic conditions without trial oversight.
- Absence of JACIE or equivalent international laboratory accreditation.
- Facilities lacking an on-site intensive care unit with transplant experience.
- Any commercial claims guaranteeing a cure or advertising painless procedures.
Essential questions to ask your clinical team:
- Is your transplant unit currently JACIE-accredited?
- How many autologous and allogeneic transplants does your centre perform annually?
- Are all inpatient rooms fitted with continuous HEPA filtration?
- What protocols exist for managing severe acute GvHD or graft failure?
- Does your quote cover all mobilisation medications, apheresis, and transfusions?
- How many weeks of post-discharge outpatient monitoring are required locally?
To review transparent administrative and inpatient costs for cellular therapies, patients can obtain a free quote tailored to their medical records. Reviewing the step-by-step breakdown of how it works ensures that donors and patients prepare thoroughly for prolonged overseas recovery.
Hospitals with Oncology in Turkey
Frequently asked questions
A peripheral blood stem cell transplant is an advanced haematological procedure that replaces diseased or depleted bone marrow with healthy blood-forming stem cells. Stem cells are mobilised into the bloodstream using growth factors and harvested through apheresis. Following intensive conditioning chemotherapy, these healthy cells are infused into the bloodstream, where they migrate to the bone marrow to restore normal blood cell production.
A PBSC transplant aims to achieve durable, long-term remission in conditions like leukaemia, lymphoma, and multiple myeloma by eradicating malignant cells and reconstituting a healthy immune system. While it can produce complete remission in many patients, therapeutic outcomes depend on disease stage, cytogenetic risk profile, and donor match quality. Relapse remains a recognized clinical possibility that requires ongoing haematological surveillance.
Peripheral blood stem cell (pbsc) transplant cost varies significantly depending on whether the procedure is autologous or allogeneic. In Turkey, autologous procedures typically range between €25,000 and €45,000, while allogeneic transplants range from €55,000 to €95,000. Final pricing depends on stem cell mobilisation difficulty, HLA typing complexity, required days in HEPA-filtered isolation, and the extent of supportive care.
An autologous transplant uses the patient's own stem cells, collected after disease remission and returned following high-dose chemotherapy, eliminating the risk of graft-versus-host disease. An allogeneic transplant uses stem cells from a matched sibling, unrelated donor, or haploidentical family member. Allogeneic transplants offer a graft-versus-tumour effect against leukaemia cells but carry substantial risks of immune incompatibility.
Initial engraftment typically occurs within 10 to 20 days post-infusion, during which patients remain in specialised isolation to prevent opportunistic infections. Discharged patients require close outpatient monitoring for the first 100 days. Full haematological and immunological recovery generally takes between six and twelve months, during which prophylactic antimicrobials, dietary restrictions, and scheduled revaccination protocols must be maintained.
Stem cell collection via apheresis is generally well-tolerated and performed without general anaesthesia. Patients may experience mild bone discomfort or fatigue during the preceding G-CSF mobilisation injections. During the multi-hour apheresis procedure, mild transient symptoms such as muscle cramping, tingling around the mouth, or chills can occur due to temporary calcium shifts from the anticoagulant, which clinical teams manage immediately with oral or intravenous calcium.
PBSC collection uses peripheral blood apheresis rather than surgical bone marrow harvesting from the pelvic bones under general anaesthesia. For patients, PBSC yields faster neutrophil and platelet engraftment, leading to shorter initial hospitalisation. However, in allogeneic settings, PBSC grafts contain more donor T-lymphocytes, which confers a potent graft-versus-tumour response but slightly increases the risk of chronic graft-versus-host disease compared with bone marrow.
Before the procedure, haematologists evaluate bone marrow biopsies, flow cytometry, cytogenetics, and organ function to confirm disease remission and patient fitness. After transplantation, regular blood tests, chimerism studies, and minimal residual disease (MRD) assays assess how effectively donor cells have taken over haematopoiesis and verify the absence of residual malignant cells. Imaging may also assess lymphoma response.
Primary risks include severe neutropenic infection, bleeding complications, organ toxicity from conditioning chemotherapy, and graft failure. In allogeneic transplantation, graft-versus-host disease (GvHD) is a major complication where donor immune cells attack host tissues, such as the skin, gastrointestinal tract, or liver. Dedicated transplant teams mitigate these risks using HEPA-filtered rooms, prophylactic antimicrobials, irradiated blood products, and targeted immunosuppression.
International patients travelling for a peripheral blood stem cell transplant Turkey usually stay between 60 and 90 days. The process requires one to two weeks for pre-transplant assessment and mobilisation, three to four weeks of inpatient isolation following conditioning and infusion, and several weeks of close outpatient surveillance to monitor blood counts, manage complications, and ensure stable graft function before international travel.
Patient stories